Opthea Ltd
OPT0.000
Close 12/08, 16:00（ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Opthea Ltd Company
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Opthea Ltd Info
Ticker SymbolOPT
Company nameOpthea Ltd
IPO dateApr 09, 1985
CEODr. Frederic (Fred) Guerard, Pharm.D.
Number of employees- -
Security typeDepository Receipt
Fiscal year-endApr 09
AddressSuite 0403, Level 4
CityMELBOURNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3141
Phone61398260399
Websitehttps://opthea.com/
Ticker SymbolOPT
IPO dateApr 09, 1985
CEODr. Frederic (Fred) Guerard, Pharm.D.
Company Executives of Opthea Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Katherine (Kathy) Connell
Ms. Katherine (Kathy) Connell
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence Gozlan
Mr. Lawrence Gozlan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Hamish George
Mr. Hamish George
Chief Financial Officer, Joint Company Secretary
Chief Financial Officer, Joint Company Secretary
--
--
Ms. Stephanie Vipond
Ms. Stephanie Vipond
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Megan Baldwin, Ph.D.
Dr. Megan Baldwin, Ph.D.
Founder, Chief Innovation Office
Founder, Chief Innovation Office
--
--
Mrs. Karen Adams, CPA
Mrs. Karen Adams, CPA
Vice President - Finance
Vice President - Finance
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Katherine (Kathy) Connell
Ms. Katherine (Kathy) Connell
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence Gozlan
Mr. Lawrence Gozlan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Hamish George
Mr. Hamish George
Chief Financial Officer, Joint Company Secretary
Chief Financial Officer, Joint Company Secretary
--
--
Ms. Stephanie Vipond
Ms. Stephanie Vipond
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Megan Baldwin, Ph.D.
Dr. Megan Baldwin, Ph.D.
Founder, Chief Innovation Office
Founder, Chief Innovation Office
--
--
Revenue Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Australia (Country)
38.64K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Regal Partners Limited
3.04%
Baker Bros. Advisors LP
1.22%
Pengana Capital Group Limited
0.16%
HSBC Global Asset Management (UK) Limited
0.06%
Millennium Management LLC
0.03%
Other
95.49%
Shareholders
Shareholders
Proportion
Regal Partners Limited
3.04%
Baker Bros. Advisors LP
1.22%
Pengana Capital Group Limited
0.16%
HSBC Global Asset Management (UK) Limited
0.06%
Millennium Management LLC
0.03%
Other
95.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.05%
Hedge Fund
1.25%
Investment Advisor/Hedge Fund
0.22%
Other
95.47%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
29
7.74M
4.52%
-1.86M
2025Q2
28
7.75M
5.03%
-1.99M
2025Q1
31
7.78M
5.06%
+284.92K
2024Q4
32
5.50M
3.68%
-5.82M
2024Q3
28
5.34M
3.58%
-5.95M
2024Q2
27
6.96M
4.69%
-4.76M
2024Q1
26
7.37M
8.95%
-4.77M
2023Q4
26
7.84M
9.52%
-4.41M
2023Q3
22
12.18M
14.75%
+1.15M
2023Q2
22
8.34M
14.29%
-198.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Regal Partners Limited
5.19M
3.04%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
2.09M
1.22%
--
--
Jun 30, 2025
Pengana Capital Group Limited
270.42K
0.16%
--
--
Apr 30, 2025
HSBC Global Asset Management (UK) Limited
105.94K
0.06%
--
--
Jun 30, 2025
Millennium Management LLC
48.33K
0.03%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
7.77K
0%
--
--
Jun 30, 2025
EP Wealth Advisors, LLC
10.00K
0.01%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
5.05K
0%
--
--
Aug 31, 2025
Morgan Stanley Smith Barney LLC
765.00
0%
--
--
Jun 30, 2025
Susquehanna International Group, LLP
--
0%
-12.31K
-100.00%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Opthea Ltd?
The top five shareholders of Opthea Ltd are:
Regal Partners Limited holds 5.19M shares, accounting for 3.04% of the total shares.
Baker Bros. Advisors LP holds 2.09M shares, accounting for 1.22% of the total shares.
Pengana Capital Group Limited holds 270.42K shares, accounting for 0.16% of the total shares.
HSBC Global Asset Management (UK) Limited holds 105.94K shares, accounting for 0.06% of the total shares.
Millennium Management LLC holds 48.33K shares, accounting for 0.03% of the total shares.
Regal Partners Limited holds 5.19M shares, accounting for 3.04% of the total shares.
Baker Bros. Advisors LP holds 2.09M shares, accounting for 1.22% of the total shares.
Pengana Capital Group Limited holds 270.42K shares, accounting for 0.16% of the total shares.
HSBC Global Asset Management (UK) Limited holds 105.94K shares, accounting for 0.06% of the total shares.
Millennium Management LLC holds 48.33K shares, accounting for 0.03% of the total shares.
What are the top three shareholder types of Opthea Ltd?
The top three shareholder types of Opthea Ltd are:
Regal Partners Limited
Baker Bros. Advisors LP
Pengana Capital Group Limited
Regal Partners Limited
Baker Bros. Advisors LP
Pengana Capital Group Limited
How many institutions hold shares of Opthea Ltd (OPT)?
As of 2025Q3, 29 institutions hold shares of Opthea Ltd, with a combined market value of approximately 7.74M, accounting for 4.52% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.51%.
What is the biggest source of revenue for Opthea Ltd?
In FY2025, the -- business generated the highest revenue for Opthea Ltd, amounting to -- and accounting for --% of total revenue.
